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UCP2Efﬁcient phagocytic clearance of apoptotic cells (efferocytosis) is essential to prevent the development of chronic
inﬂammation and autoimmunity. Glucocorticoids are widely used in the therapy of chronic inﬂammatory
diseases, and increasing evidence suggests that they act partly via enhancing efferocytosis by macrophages.
Glucocorticoids were previously shown to promote both protein S- and MFG-E8-dependent efferocytosis.
Since previous studies in our laboratory have demonstrated that glucocorticoids induce the expression of
retinaldehyde dehydrogenases inmacrophages, in the present experiments the possible involvement of retinoids
in the glucocorticoid-induced efferocytosis was studied in mouse bone marrow derived macrophages. Here we
show that glucocorticoids promote not only short-term, but also long-term clearance of apoptotic cells. Glucocor-
ticoids seem to directly induce the expression of the phagocytosis-related genes MERTK, C1q, UCP2, and the
transcription factor C/EBPβ. C/EBPβ contributes to the further induction of the phagocytosis-related genes, and
is required for the induction of lipid sensing receptors LXRs, PPARδ, RARα, RXRα and RALDH1, the latter one in
an LXR- and RARα-dependent manner. Glucocorticoid-induced enhancement in long-term efferocytosis was de-
pendent on the induction of lipid sensing receptors known to be triggered by the lipid content of the engulfed
cells to enhance phagocytic capacity. Retinoids did not affect the glucocorticoid-induced short term phagocytosis
of apoptotic cells, but were required for the glucocorticoid-induced enhancement of efferocytosis during prolonged
clearance of apoptotic cells by promoting efﬁcient LXR and PPARδ upregulation. Our data indicate that retinoids
could be considered as potential promoters of the efﬁcacy of glucocorticoid treatment in inﬂammatory diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Efﬁcient execution of apoptotic cell death followed by efﬁcient clear-
ance called efferocytosis mediated by professional macrophages plays a
key role in maintaining tissue homeostasis. As cells become apoptotic,
they undergo dramatic changes in the composition of their surface,rophage; C1qb, complement
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[1]. Since there is no one single characteristic cell surface change on
the apoptotic cells, macrophages recognize multiple cell surface alter-
ations by utilizing an array of phagocytic receptors acting simultaneous-
ly [2,3]. The redistribution of phosphatidylserine on the surface of the
apoptotic cell is the best characterized mark that distinguishes cellular
life from death [4]. Many of the macrophage receptors recognize
phosphatidylserine or its oxidized form binding to them directly, or
indirectly via bridging molecules, such as milk fat globule EGF-factor 8
(MFG-E8) [5], thrombospondin-1 [6], protein S [7] or complement 1q
(C1q) [8]. Macrophages are capable of both expressing the cell surface
receptors and releasing their bridging molecules for the recognition
and engulfment of apoptotic cells. CD14 [9] or Tim4 [10] phagocytosis
receptors mediate tethering, while other receptors, such as CD36 [11],
integrin β3 [6], integrin β5 [12], Mer tyrosine kinase (MERTK) [13],
stabilin-2 [14] and CD91 [15] activate two evolutionally conserved
parallel signaling pathways which promote cytoskeletal reorganization
via the activation of the low molecular weight GTPase Rac1 [16].
Macrophages are exposed to varying numbers of apoptotic cells
in vivo, and therefore they need a sensing mechanism that prepares
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Increasing evidence suggests that the receptors that sense the amount
of apoptotic cell material engulfed and enhance the phagocytic capacity
of macrophages in response are the lipid sensing receptor liver X recep-
tor (LXR) [17], and the peroxisome proliferator-activated receptors
(PPAR)γ [18] and δ [19]. Lipid sensing receptors belong to the nuclear
retinoid X receptor (RXR) heterodimer family and can be triggered in-
dependently by both the lipid content of the engulfed cells on the LXR
or PPAR, and by a vitamin A (retinol) derivative on the RXR ligand
binding sites [20]. It is believed that the RXR ligand in tissues is a 9-cis
retinoic acid, which is thought to be produced by a non-enzymatic
reaction from all-trans retinoic acid [21]. All-trans retinoic acid is an ox-
idative derivative of retinol, and is generated from it by two subsequent
dehydrogenase steps [22]. Triggering of these nuclear receptors leads to
enhanced expression of phagocytic receptors and bridging molecules
such as MERTK, C1q, CD36, transglutaminase 2, Tim-4, stabilin-2 and
CD14 in macrophages [17–19,23]. In the LXR signaling pathway their
upregulation ismediated by retinoids produced via retinaldehydedehy-
drogenases (RALDHs) [23]. Engulfment of apoptotic cells delivers excess
materials into the phagocytes. As a result, lipid-sensing receptors need
also to regulate the transcription of genes involved in the their metabo-
lism [24,25]. Thus, enhanced expression of ATP-binding cassette
transporter A1 induced by LXRs for the export of excess cholesterol
[26], accelerated fatty acid oxidation [25], or increased expression of
uncoupling protein 2 (UCP2) induced by PPARδ [25] for the dissipation
of H+ gradient to reduce mitochondrial membrane potential [27]
will meet the demand of proper handling the engulfed apoptotic cell
material during prolonged phagocytosis.
Glucocorticoids are powerful in the treatment of a range of inﬂamma-
tory conditions, so far explained by their ability to inhibit recruitment of
inﬂammatory cells, to downregulate proinﬂammatory cytokine expres-
sion and to induce apoptosis in inﬂammatory cells. However, glucocorti-
coids were also shown to enhance phagocytosis of apoptotic cells [28].
During the apoptotic program autoantigens are produced by apoptotic
cells and will be released if they are not cleared efﬁciently leading to
initiation ormaintenance of chronic inﬂammatory conditions [29]. In ad-
dition, efﬁcient neutrophil clearance contributes to the resolution of
acute inﬂammation [30]. Thus enhancing efferocytosis by macrophages
might contribute to the anti-inﬂammatory effects of glucocorticoids.
Dexamethasone (Dex) was shown to promote both protein S [31]
and MFG-E8-dependent [32] phagocytosis of apoptotic cells. In addi-
tion, it was also shown to enhance the cell surface expression of the
phagocytic receptor CD91 [33]. Previous studies in our laboratory have
shown that following in vivo thymocyte apoptosis induction by Dex
macrophages engulﬁng apoptotic cells produce retinoids, but adminis-
tration of Dex alone is also capable of upregulating the expression of
RALDHs in macrophages [34]. The present studies were undertaken to
investigate whether retinoid production contributes to the enhanced
phagocytosis of apoptotic cells induced by Dex. Our results indicate
that glucocorticoids upregulate the expression of lipid sensing nuclear
receptors to promote continued phagocytosis of apoptotic cells and
retinoids act in a positive autoregulatory loop to enhance their
transcriptional activity.
2. Materials and methods
2.1. Reagents
All reagentswere obtained fromSigma-Aldrich (Budapest, Hungary)
except when indicated otherwise.
2.2. Experimental animals
The experiments were carried out with 4-wk-old or 2- to 4-mo-old
C57B6 mice. In some experiments RARα knockout mice [35] and
RARE-hsp68-lacZ reporter transgenic mice [36] were also used. Micewere maintained in speciﬁc pathogen-free condition in the Central
Animal Facility and all animal experiments were approved by the
Animal Care and Use Committee of University of Debrecen (DEMÁB).
2.3. Bonemarrow derivedmacrophage (BMDM) cell culture and treatment
Bone marrow progenitors were obtained from the femurs of 2- to
4-mo-old mice lavage with sterile physiological saline. Cells were
allowed to differentiate for 5 d in DMEM supplemented with 10%
FBS, 20% conditioned medium derived from L929 cells, 2 mM gluta-
mine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 °C in
5% CO2. Non-adherent cells were washed away after three days.
BMDMs were treated with 1 μM dexamethasone-acetate, 25 μM
diethylaminobenzaldehyde (DEAB) to block aldehyde dehydrogenase
enzyme activities, or vehicle (DMSO) for the indicated time periods. In
some experiments 1 μM GSK3787 (Tocris), a PPARδ antagonist, 1 μM
AGN193109, a pan RAR antagonist was used. For prolonged phagocyto-
sis experiments apoptotic thymocytes were added to BMDMs in 5:1
(apoptotic cells:macrophage) ratio for 3 h, then apoptotic cells were
washed away extensively. For the inhibition of new protein synthesis
20 μM cycloheximide (CHX) was used.
2.4. X-gal staining of dexamethasone-treated BMDMs
BMDMs derived from RARE-hsp68-lacZ reporter transgenic
mice were treated with 1 μM dexamethasone-acetate, 25 μM
diethylaminobenzaldehyde (DEAB) to block aldehyde dehydrogenase
enzyme activities, or vehicle (DMSO) for 24 h. Cells were then ﬁxed
with 0.25mMglutaraldehyde for 5min on ice. Fixed cells were incubat-
ed at 37 °C for 24 h in X-gal staining solution (35 mM potassium
ferrocyanide, 35 mM potassium ferricyanide, 2 mM MgCl2, 0.02%
Nonidet P-40, 1 mg/ml X-gal). Images were taken using an AMG EVOS
inverted microscope at 20× magniﬁcation.
2.5. In vitro apoptotic cell phagocytosis
BMDMs were stained for 24 h with 5 μM CellTracker Orange
(5-(and-6)-[([4-chloromethyl]benzoylamino)tetramethylrhodamine];
Invitrogen). To generate apoptotic thymocytes, thymi were collected
from 4-wk-old C57B6 mice, thymocytes were isolated and cultured
for 24 h (107 cells/ml) in RPMI 1640 medium supplemented with
2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin,
and 10 μM carboxyﬂuorescein diacetate succinimidyl ester (CFDA-SE;
Invitrogen) in the absence of serum. CFDA-stained apoptotic thymo-
cytes were added to the BMDMs in 5:1 (apoptotic cells/macrophage)
ratio for 30 min (or for 45 min in transfected macrophages). After
coculture, apoptotic cells were washed away and macrophages were
detached by trypsinization. Percentage of macrophages engulﬁng
apoptotic cells was analyzed on a Becton Dickinson FACSCalibur. For
determining prolonged phagocytosis, macrophages were exposed to
non-labeled apoptotic thymocytes for 3 h, and phagocytic activity was
measured in the following 30 min by replacing the non-labeled
apoptotic cells with CFDA labeled ones.
2.6. Analysis of mRNA expression
Total RNAwas isolated from BMDMs by TRI reagent according to the
manufacturer's guidelines. Total RNAwas reverse transcribed into cDNA
using High Capacity cDNA Reverse Transcription Kit (Life Technologies,
Budapest, Hungary) according to the manufacturer's instructions.
Quantitative RT-PCR was carried out in triplicate using pre-designed
FAM-labeled MGB assays (Life Technologies, Budapest, Hungary) on a
Roche LightCycler LC 480 real-time PCR instrument. Relative mRNA
levels were calculated using the comparative CT method and were
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA.
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Five-day-matured BMDMs were transfected with ON-TARGETplus
SMARTpool siRNA speciﬁc for mouse LXRα and LXRβ or C/EBPβ and
ON-TARGETplus Non-targeting Control Pool (Dharmacon) using the
DharmaFECT 1 Transfection Reagent (Dharmacon) according to the
DharmaFECT's Transfection Protocol. siGLOGreen (6-FAM) Transfection
Indicators are specially designed for nuclear localization for a clear
signal of successful transfection. siGLO Green Transfection Indicator
(50 nM) was transfected into BMDMs (0.3 μl/100 μl well). After 2 h,
transfection efﬁciency (ﬂuorescent signal) was detected by FACS
analysis. At 24/48 h after transfection, cells were treated with 1 μM
dexamethasone-acetate (Dex) or vehicle (DMSO) for 18/24 h and har-
vested for detecting themRNA/protein levels of LXR or CCAAT/enhancer
binding protein (C/EBP)β of transfected BMDMs by quantitative PCR/
Western blot analysis, respectively. To determine the effect of LXR or
C/EBPβ gene silencing on the mRNA expression levels of various
glucocorticoid-induced genes, at 48 h after transfection, cells were
treated with Dex (1 μM) or vehicle (DMSO) for the indicated time
periods.
2.8. Western blot analysis
BMDMs were homogenized in ice-cold lysis buffer containing
0.5% Triton X-100. Protein concentration of samples was diluted to
2mg/ml, then the sampleswere boiledwith an equal volume of Laemmli
buffer. Electrophoresis was performed in 15% SDS-polyacrylamide gel.
Separated proteins were transferred to an Immobilon-P transfer mem-
brane (Millipore, Budapest, Hungary) and were probed with anti-
mouse LXRα/β (ABGENT), PPARδ (Abcam), C/EBPβ (Biolegend) or
GAPDH antibodies. Protein bands were visualized by Immobilon West-
ern Chemiluminescent HRP substrate (Millipore, Budapest, Hungary).
2.9. Statistical analyses
All the data are representative of at least three independent ex-
periments carried out on three different days. Values are expressed
as mean ± SEM. p values were calculated by using unpaired Student's
t-test.
3. Results
3.1. Retinoid production is required for the glucocorticoid-induced
enhancement of efferocytosis during prolonged clearance of apoptotic cells
Since previously we observed that exposure of macrophages to Dex
results in induction of RALDHs [34], we decided to investigate whether
Dex treatment indeed induces retinoid synthesis in macrophages. For
this purpose BMDMs derived from RARE-hsp68-lacZ reporter transgen-
ic mice were exposed to 1 μM Dex for 24 h either alone or in the
presence of 25 μM DEAB, an inhibitor of aldehyde dehydrogenase
enzyme activities. In these mice, lacZ expression demonstrates the
endogenous retinoid-dependent transcriptional activity. As shown in
Fig. 1A, BMDMs exposed to Dex for 24 h expressed lacZ demonstrated
by X-gal staining, while neither the vehicle control, nor the DEAB co-
treated cells did so. These data indicate that Dex induces physiologically
relevant retinoid synthesis in BMDMs, and DEAB in the applied concen-
tration can completely block it.
Next we decided to investigate whether inhibition of retinoid syn-
thesis by DEAB affects the Dex-induced enhancement in efferocytosis.
As it was published previously [37], exposure of bone marrow derived
macrophages to 1 μM Dex signiﬁcantly enhanced their capacity to en-
gulf apoptotic thymocytes by increasing the percentage ofmacrophages
engulﬁng apoptotic cells (Fig. 1). The effect was time-dependent
and the maximal enhancement was seen following 18 h exposure to
Dex. As seen in Fig. 1B–E, administration of DEAB did not affect theglucocorticoid-induced enhancement of efferocytosis, if efferocytosis
was detected in the ﬁrst 30 min after the indicated times of Dex treat-
ment. That is why we tested the effect of glucocorticoids also on
prolonged efferocytosis by detecting a 30 min apoptotic cell uptake fol-
lowing 3 h continuous efferocytosis. To do so, macrophages were ex-
posed to CFDA-labeled macrophages only during the last 30 min of
the continued phagocytosis. Prolonged phagocytosis for 3 h alone only
slightly increased the percentage of macrophages engulﬁng apoptotic
cells (Fig. 1D,E). If, however, macrophages were pretreated with Dex,
an enhancement in the percentage of engulﬁng cells was observed,
and this enhancement was completely inhibited by DEAB. These data
indicate that retinoids mediate the effect of glucocorticoids on the en-
hancement of efferocytosis during prolonged phagocytosis of apoptotic
cells.
3.2. Glucocorticoids induce the expression of various lipid sensing nuclear
receptors prior to that of RALDH1
Our previous studies have also shown that triggering various
lipid sensing nuclear receptors also induces the expression of RALDHs
[23,34]. Thus we asked, whether glucocorticoids affect the expression
of RALDHs via regulating the expression and activity of lipid sensing nu-
clear receptors. As shown in Fig. 2A andB,while Dex downregulated the
expression of PPARγ (data not shown), it signiﬁcantly induced the
expression of both LXRs and PPARδ and their heterodimeric partner
RXRα with a peak at around 12 h. In addition, the expression of
CYP27, a mitochondrial sterol 27-hydroxylase which produces a ligand
(27-hydroxycholesterol) for LXRs [38]was also induced (Fig. 2C).While
the induction of these nuclear receptors was completely inhibited by
pretreatment with 20 μM cycloheximide, a protein synthesis inhibitor
(data not shown), the induction of CYP27 was only partially inhibited
(Fig. 2D) indicating that it might be a direct glucocorticoid target gene.
Indeed, in the promoter of the human CYP27 gene the presence of a pu-
tative glucocorticoid response elementwas reported [39]. The induction
of RALDH1 by Dex followed in time that of the nuclear receptors
resulting in a continuous increase in its expression (Fig. 2A).
3.3. Induction of RALDH1 requires the expression of LXR-induced RARα and
Dex-induced C/EBPβ
Previous studies have shown that RALDH1 expression can be regu-
lated either by sterol response element binding protein (SREBP)-1c
[40] or by retinoic acid receptor (RAR)α and CCAAT/enhancer binding
protein (C/EBP)β simultaneously [41]. Since LXRs can directly promote
transcription of both SREBP-1c through two LXR response elements in
its promoter [42] and that of RARα [43], we decided to investigate
whether LXRs are involved in the Dex-induced increase in the
expression of RALDH1. Though Dex induced the expression of LXRs
and the enzyme that can produce a ligand for them, the expression of
SREBP-1c was not altered by Dex (data not shown). On the other
hand, as shown in Fig. 3A, the expression of both RARα and C/EBPβ
was enhanced in macrophages following Dex exposure. While
preincubation with cycloheximide completely inhibited the induction
of RARα by Dex (data not shown), administration of it led rather to an
increase in C/EBPβmRNA, which suggests that a labile negative protein
factor(s) is involved in regulation of the C/EBPβmRNA levels. Cyclohex-
imide further augmented the increase in C/EBPβmRNA by Dex indicat-
ing that its induction is apparently independent of ongoing protein
synthesis (Fig. 3B), and glucocorticoids might promote the induction
of C/EBPβ by suppressing the transcription of the labile inhibitory
protein (s).
To investigate further the role of C/EBPβ, LXRs and RARα in the in-
duction of RALDH1byDex, the effect of silencing of LXRs andC/EBPβ ex-
pressions, and inhibition of the transcriptional activity or genetic knock
out of RARα was studied on the Dex-induced RALDH1 expression. The
transfection efﬁciency for the siRNAs with the Dharmafect transfection
Fig. 1. Inhibition of retinoic acid synthesis prevents the glucocorticoid-induced enhancement in long-term efferocytosis. (A) Bone marrow derived macrophages from RARE-hsp68-lacZ
reporter-carrying mice produce physiologically relevant concentrations of retinoids when they are exposed to 1 μM Dex for 24 h, and this pathway is completely inhibited by addition
of DEAB (25 μM), an RALDH inhibitor. The appearance of the β-galactosidase protein was demonstrated by X-gal staining. Images were taken using an AMG EVOS inverted microscope
at 20×magniﬁcation. Bonemarrow derived macrophages were treated with DEAB (25 μM), Dex (1 μM) alone or together for (B) 6 h, (C) 12 h, (D) 18 h and (E) 24 h. To study continued
efferocytosis, in the indicated experiments macrophages were ﬁrst exposed to non-ﬂuorescent apoptotic thymocytes during the last 3 h of Dex treatment before being exposed to CFDA-
labeled thymocytes. % of macrophages engulﬁng apoptotic cells was then determined as described in Materials and methods. The increase in the percentage of engulﬁngmacrophages is
compared to that of the non-treated controls (10.9± 0.8%) and is expressed as fold induction showing themean± SEM of 3 separate experiments. Signiﬁcantly different from respective
control: *p b 0.05, **p b 0.01, ***p b 0.001.
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LXRs and C/EBPβ on mRNA and protein levels are shown in Fig. 3D and
E, respectively.
As shown in Fig. 3F, silencing of C/EBPβ prevented the induction of
LXRα by Dex indicating that its induction by Dex is mediated C/EBPβ.
Silencing of LXRs prevented the induction of RARα, in line with the
observation that RARα is an LXR target gene [43]. In linewith our obser-
vation that silencing of C/EBPβ prevented the induction of LXRs by Dex,
silencing of C/EBPβ also prevented the induction of RARα by Dex
(Fig. 3G). On the other hand, silencing of LXRs did not prevent the
Dex-induced enhancement in the expression of RXRα indicating that
RXRα is not an LXR target gene. However, its induction by Dex was
also C/EBPβ-dependent (Fig. 3H).Silencing of both LXRs and C/EBPβ, which are required for RARα in-
duction by Dex (Fig. 3G), prevented the Dex-induced increase in the
RALDH1 expression (Fig. 3I). Similarly, administration of AGN109, a
pan RAR antagonist (Fig. 3J) or genetic knock out of RARα (Fig. 3K)
also prevented the induction of RALDH1 by Dex suggesting a determin-
ing role of RARα in the regulation of RALDH1 expression. Altogether
these data indicate that glucocorticoids induce the expression of
C/EBPβ in macrophages which contributes to the induction of both
LXRs and RXRα. Glucocorticoids also induce the expression of CYP27,
which might provide an endogenous ligand for the LXR. RARα is in-
duced in an LXR/RXR-dependent manner and is required for the induc-
tion of RALDH1. Though previous studies indicated that C/EBPβ can also
be directly involved in the induction of RALDH1 [41], since it is also
Fig. 2. Glucocorticoids induce the expression of CYP27, several lipid sensing nuclear receptors and RALDH1 inmacrophages. Macrophages were treated with Dex (1 μM) for the indicated
time periods.mRNA expressions of (A) RALDH1, LXRα andβ, (B) PPARδ and RXRα, and (C) CYP27were determined by qRT-PCR analysis using GAPDH as reference gene.(D)Macrophages
were treatedwith Dex (1 μM) together with cycloheximide (20 μM) for 4 h to inhibit new protein synthesis. mRNA levels of CYP27were determined by qRT-PCR analysis using GAPDH as
reference gene. Results are expressed asmean±SEMof at least 3 separate experiments. Signiﬁcantly different from respective control: *pb 0.05, **p b 0.01, ***p b 0.001 for RALDH1, RXRα
or CYP27, +p b 0.05, ++p b 0.01 for LXRα or PPARδ, ƒp b 0.05, ƒƒp b 0.01 for LXRβ. Protein levels detected byWestern blot for LXRs and PPARδ following a 24 hDex treatment are also shown
in (A) and (B), respectively.
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our data cannot provide evidence for its direct involvement in the
regulation of RALDH1 expression by Dex.
3.4. Glucocorticoids induce the expression of MERTK, C1q and UCP2 in
BMDMs in a C/EBPβ-dependent manner. The long-term induction of UCP2
involves PPARδ, while that of C1q requires LXR nuclear receptors
Next we decided to investigate that the expression of which
efferocytosis-related molecules is affected by Dex treatment. In line
with previous publications [31,44] Dex induced the expression of
MERTK (Fig. 4A). Its induction was inhibited by preincubation with
cycloheximide (Fig. 4B) and by C/EBPβ silencing (Fig. 4D) indicating
that C/EBPβ contributes to its induction by Dex. Though MERTK was
found to be a direct LXR target gene [17], silencing of LXRs, did not
affect its Dex-induced expression signiﬁcantly (Fig. 4D) indicating
that C/EBPβ contributes to its induction independently of its effect
on LXR expression. In addition, inhibition of the transcriptional ac-
tivity of PPARδby GSK3787 also had no effect on MERTK expression
(Fig. 4C).
In line with a previous publication [44,45], Dex also induced the
expression of the bridging molecule C1q (Fig. 4A). Induction of C1q by
Dex was not inhibited by cycloheximide indicating that new protein
synthesis is not required for its early induction (Fig. 4B). But the presence
of C/EBPβ and LXRs was required for its long term induction detected
at 21 h (Fig. 4D), while PPARδ did not seem to be involved in its Dex-
induced regulation (Fig. 4C).
Finally, we detected the glucocorticoid-dependent induction of
UCP2 (Fig. 4A). Though its short term induction, similar to that of C1q,
was independent of new protein synthesis (Fig. 4B), its long-term in-
duction detected at 21 h required both PPARδ (Fig. 4C) and C/EBPβ(Fig. 4D). The expression of other phagocytosis-related molecules in
bone marrow derived macrophages, such as MFG-E8, CD36, CD91,
stablin-2 and CD14 was not altered by Dex treatment, while that of
transglutaminase 2, integrin β3, and TIM4 was decreased (data not
shown). Our data conﬁrm previous ﬁndings that glucocorticoids en-
hance a selective set of phagocytosis relatedmolecules and demonstrate
that their long-term induction by glucocorticoids is related to the
induction of C/EBPβ and lipid sensing nuclear receptors.
3.5. LXRs and PPARδ mediate the glucocorticoid-induced increase in the
phagocytic capacity during prolonged efferocytosis
Since previous studies have shown that LXRs and PPARδ triggered by
the apoptotic cell content can mediate the enhanced efferocytosis
during continued phagocytosis [17,19], and Dex signiﬁcantly induced
the expression of these nuclear receptors, we decided to investigate
whether silencing of LXRs or inhibition of the transcriptional activity
of PPARδ by the PPARδ antagonist GSK3787 (1 μM) could interfere
with the efferocytosis enhancing effect of glucocorticoids. As shown in
Fig. 5A, silencing of LXRs or inhibition of the transcriptional activity of
PPARδ by GSK3787 had no effect on efferocytosis if it was detected
directly after 24 h preincubation of macrophages with Dex. It is in line
with the ﬁnding that these nuclear receptors do not affect the
glucocorticoid-induced expression of MERTK, which was shown pre-
viously to drive the glucocorticoid-induced enhancement in short-
term efferocytosis [31]. On the other hand, silencing of C/EBPβ
which prevented the glucocorticoid-induced induction of MERTK, also
prevented the effect of glucocorticoids on the short term efferocytosis.
If, however, efferocytosis was detected during continued phagocytosis,
both silencing of LXRs and inhibition of the transcriptional activity of
PPARδ interfered with the glucocorticoid effect (Fig. 5B). Silencing of
Fig. 3. C/EBPβ, LXRs and RARα contribute to the glucocorticoid-induced RALDH1 induction in bonemarrow derivedmacrophages. (A)Macrophageswere treated with Dex (1 μM) for the
indicated time periods. mRNA expression levels of C/EBPβ or RARαwere determined by qRT-PCR analysis using GAPDH as reference gene. (B)Macrophageswere treatedwith Dex (1 μM)
together with cycloheximide (20 μM) for 4 h to inhibit new protein synthesis. mRNA levels of C/EBPβ were determined by qRT-PCR analysis using GAPDH as reference gene.
(C) Macrophages were transfected with siGLO Green transfection indicator (Dharmacon) by Dharmafect transfection reagent to determine the transfection efﬁciency of cells. D, Macro-
phages were transfected with non-targeting siRNA, LXRα and LXRβ siRNA together or with C/EBPβ siRNA by Dharmafect transfection reagent. At 24 h after the transfection, cells were
treated with Dex for 24 h to determine mRNA expression levels of LXR and C/EBPβ by qRT-PCR analysis. E, Macrophages were transfected with non-targeting siRNA, LXRα and LXRβ
siRNA (Dharmacon) together orwith C/EBPβ siRNA (Dharmacon) by Dharmafect transfection reagent. At 48 h after transfection, cells were treatedwith Dex for 24 h to determine protein
level of LXR and C/EBPβ byWestern blot analysis. (F–I) Macrophages were transfected with the indicated siRNA. At 48 h after the transfection, cells were treated with Dex for 18 h to de-
termine mRNA expression levels of (F) LXRα, (G) RARα, (H) RXRα and (I) RALDH1 by qRT-PCR analysis using GAPDH as reference gene. (J) Macrophages were treated with Dex (1 μM)
and with the pan RAR antagonist AGN109 (1 μM) as indicated for 24 h. mRNA expression levels of RALDH1 were determined by qRT-PCR analysis using GAPDH as reference gene.
(K) Macrophages derived from wild type or RARα KO mice were treated with Dex (1 μM) for 24 h. mRNA expression levels of RALDH1 were determined by qRT-PCR analysis using
GAPDH as reference gene. Each bar represents mean ± SEM of 3 separate experiments. Signiﬁcantly different from respective control: *p b 0.05, **p b 0.01, ***p b 0.001. n.s. = not
signiﬁcant. n.d. = not determined. nt = non-targeted.
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and PPARδ, also prevented the enhancing effect of glucocorticoids on
long-term efferocytosis. These data indicate that nuclear receptor
LXRs and PPARδ mediate the enhancing effect of glucocorticoids on
the efferocytosis during prolonged phagocytosis.3.6. Prolonged phagocytosis induces the expression of LXRα, RXRα, RARα
and PPARδ, which is further enhanced in the presence of dexamethasone
Since our results indicate that lipid sensing receptors are required
for the glucocorticoid-induced enhancement of efferocytosis during
Fig. 4.Glucocorticoids induce the expression of MERTK, C1q and UCP2 in BMDMs in a C/EBPβ-dependentmanner. The long-term induction of UCP2 involves the PPARδ, while that of C1q
the LXR nuclear receptors. (A) Macrophages were treated with Dex (1 μM) for the indicated time periods. mRNA expressions of MERTK, C1qb, and UCP2 were determined by qRT-PCR
analysis using GAPDH as reference gene. Gene expression changes are expressed as mean ± SEM of at least 3 separate experiments. Signiﬁcant differences, *p b 0.05, **p b 0.01, ***p b
0.001, are shown for MERTK, +p b 0.05, ++p b 0.01, +++p b 0.001 for C1qb and xp b 0.05, xxp b 0.01 for UCP-2. (B) Macrophages were treated with Dex (1 μM) alone or in combination
with CHX (20 μM) for 4 h to inhibit new protein synthesis. mRNA expression levels of the indicated genes were determined by qRT-PCR using GAPDH as reference gene.(C)Macrophages
were treated with Dex (1 μM) alone or in combination with GSK3787 (1 μM) for 21 h, then mRNA expression levels of the indicated genes were determined by qRT-PCR using GAPDH as
reference gene. (D)Macrophages were transfectedwith the indicated siRNAs, incubated for 48 h after transfection, and then they were treated with Dex (1 μM) for 21 h to determine the
mRNA expression levels ofMERTK, C1qb andUCP2 by qRT-PCR using GAPDH as reference gene. Each bar representsmean± SEMof at least 3 separate experiments. Signiﬁcantly different
from respective control: *p b 0.05, **p b 0.01, ***p b 0.001, n.s. = not signiﬁcant.
579É. Garabuczi et al. / Biochimica et Biophysica Acta 1853 (2015) 573–582prolonged clearance of apoptotic cells, we decided to investigate, how
the expression of the nuclear receptors does alter during prolonged
clearance. As it is shown in Fig. 6, prolonged phagocytosis for 3 h
alone induced the expression of LXRα, PPARδ, RARα and RXRα, since
the lipid content of the apoptotic cells activated both the LXR and the
PPARδ signaling pathways. In Dex-exposed cells their expression was
further induced. Similar pattern of changes was observed in the expres-
sion of UCP2.Fig. 5.Glucocorticoid-induced long-term efferocytosis ismediated via LXRs and PPARδ. δ. (A)Ma
for 48 h. Then they were exposed to 1 μM Dex for 24 h. Half of the non-targeting siRNA treate
Phagocytosis was determined as it was described in Materials and methods. (B) To determine
also exposed to non-ﬂuorescent apoptotic thymocytes during the last 3 h of Dex induction befor
of engulﬁng macrophages is compared to that of the non-treated controls (20.6 ± 1.9%) an
⁎Signiﬁcantly different from respective control p b 0.05. n.s. = not signiﬁcant.3.7. Inhibition of RALDHs by DEAB decreases both the glucocorticoid-
induced and the prolonged phagocytosis-induced expression of nuclear
receptors
Next we tested, how the expression of the Dex-sensitive nuclear
receptors is altered, if RALDHs are inhibited by DEAB. As shown in
Fig. 6, inhibition of RALDHs interfered with both the glucocorticoid-
and the prolonged phagocytosis-induced increase in lipid sensingcrophageswere transfectedwith non-targeting siRNA, LXRα andβ siRNA or C/EBPβ siRNA
d macrophages received Dex in combination with GSK3787 (1 μM), a PPARδ antagonist.
prolonged phagocytosis, macrophages were treated as above, but in addition they were
e determining phagocytosiswith CFDA-labeled thymocytes. The increase in the percentage
d is expressed as fold induction showing the mean ± SEM of 3 separate experiments.
Fig. 6. Inhibition of retinoic acid synthesis prevents glucocorticoid-induced expression of lipid sensitive nuclear receptors and UCP2. Macrophages were treated with Dex (1 μM) and/or
DEAB (25 μM) for 24 h. Half of themacrophages were additionally exposed to apoptotic thymocytes during the last 3 h of incubation.mRNA levels of the indicated genes were determined
by qRT-PCR analysis using GAPDH as reference gene. Each bar represents mean ± SEM of at least 3 separate experiments. Signiﬁcantly different from respective control: *p b 0.05,
**p b 0.01, ***p b 0.001. n.s. = not signiﬁcant.
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autoregulatory role in both pathways. Similar expression pattern was
observed for UCP2, a PPARδ target gene as well. Our data conﬁrm our
previous ﬁndings that the LXR signaling pathway involves a retinoid-
dependent autoregulatory ampliﬁcation loop [23], and we extended
now this observation also for the glucocorticoid-induced lipid sensing
signaling pathways.
4. Discussion
In healthy individuals billions of cells die by apoptosis every day.
Removal of the dead cells by efferocytosis must be efﬁcient to prevent
secondary necrosis and the consequent release of proinﬂammatory
cell contents that damages the tissue environment and provokes auto-
immunity. In addition, sensing and removal of apoptotic cells generally
induce an anti-inﬂammatory response. As a consequence, improper
clearance of apoptotic cells being the result of either genetic anomalies
and/or a persistent disease state, contributes to the establishment and
progression of autoimmune diseases [46]. Most of these diseases re-
spond verywell to glucocorticoid treatment. Thoughmanymechanisms
have been discovered throughwhich glucocorticoidsmediate downreg-
ulation of inﬂammatory responses [28], increasing evidence suggest
that enhancing clearance of apoptotic cells might be one of them.
Previous studies have shown that glucocorticoids are capable of
enhancing short-term phagocytosis of apoptotic cells by increasing the
expression of Mer tyrosine kinase family phagocytic receptors [31,44],the expression level of MFG-E8 [32] and the cell surface expression of
the phagocytic receptor CD91 [33]. We could conﬁrm the enhancing ef-
fect of glucocorticoids on the short-term efferocytosis of apoptotic cells
and the induction of MERTK, but not that of the induction of MFG-E8 in
BMDMs. In line with our observation, if MFG-E8 knockout mice were
treated for a week with dexamethasone which affects both macro-
phages and induces thymocyte apoptosis in the thymus, no alterations
were detected in the rate of in vivo efferocytosis or in the residual
thymic size [32]. But in thioglycollate-elicited macrophages the
dexamethasone response was found to be MFG-E8 dependent [32],
andwe also found an increase in MFG-E8 expression in peritoneal mac-
rophages in response to Dex treatment indicating that the Dex response
on MFG-E8 might be macrophage type speciﬁc.
However, we could detect the induction of another bridging
molecule C1q [8]. C1q was reported to bind to and activate the CD91
phagocytic receptor [15], the cell surface expression of which was
shown to be induced by Dex [33]. While CD91 was reported to trigger
the GULP-dependent [47], MERTK contributes to the Dock/Elmo-
dependent signaling pathway of Rac activation by promoting integrin
β5 signaling [48]. Thus simultaneous induction of MERTK and C1q by
Dexmight enhance efferocytosis by promoting both signaling pathways
which lead to Rac activation. In addition to being a CD91 ligand, C1qwas
reported recently to promote MERTK-dependent efferocytosis also via
triggering the adiponectin signaling pathway [49]. This signaling
pathway involves activation of AMP activated protein kinase [50],
which also promotes phagocytosis of apoptotic cells [51]. Because the
Fig. 7. Proposed model for the glucocorticoid-induced enhancement of phagocytosis
of apoptotic cells by macrophages. Triggering of glucocorticoid receptors leads to
the up-regulation of potential glucocorticoid-target genes such as MERTK, UCP2, CYP27
and C1q, and induces the expression of C/EBPβ possibly by repressing the transcription
of its labile transcription inhibitory protein. C/EBPβ then contributes to the expression
of all these genes as well as to the induction of lipid sensing nuclear receptors LXR/
RXRα and PPARδ/RXRα. CYP27 produces an endogenous ligand for triggering LXR leading
to the up regulation of RARα and then to the consequent up-regulation of RALDH1. The
retinoids produced act back via a positive autoregulatory loop to enhance the expression
of all the lipid sensing receptors. PPARδ then contributes to the long-term induction of
UCP2, while LXRs to that of C1q.
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scription factor induced by Dex (Fig. 4D), silencing of it prevented the
enhancing effect of Dex on the short term phagocytosis (Fig. 5A).
In addition to the phagocytosis receptors and bridging molecules,
our novel ﬁnding is that Dex also upregulates the expression of several
nuclear receptors, such as LXRs, RXRα and PPARδ, together with CYP27,
all of them in a C/EBPβ-dependent manner (Fig. 7). The C/EBPβ tran-
scription factor has been previously shown to be critical formacrophage
differentiation and function [52] and our data indicate that glucocorti-
coids also upregulate C/EBPβ to initiate or to promote glucocorticoid-
dependent transcription. We demonstrated that PPARδ was required
for the upregulation of UCP2 (Fig. 4C), while LXRs for that of C1q and
RARα, and consequently RALDH1 (Fig. 3). The regulation of other
RALDHs was not investigated in our study, but the retinoids produced
by RALDHs promoted the induction of the expression of all these nucle-
ar receptors via a positive autoregulatory loop (Fig. 6). The mechanism
of this feedback induction was not studied in our experiments, but it
is known that both LXRs and PPARδ are permissive nuclear receptors,
thus they can be activated by the RXR retinoid ligand binding site as
well [20]. In addition, at least for LXRα it was demonstrated that LXR
binding sites also exist in its promoter. Thus following ligation, LXRs
promote their own transcription via an autoregulatory loopmechanism
[53].
But Dex-induced short-term efferocytosis did not require de novo
retinoid synthesis (Fig. 1). Neither was the short-term phagocytosis
LXR- or PPARδ-dependent (Fig. 5A). The reason for this was that
1.) the induction ofMERTK that drives the enhancement in efferocytosis
by Dex [31] was LXR- and PPARδ-independent 2.) the metabolic chang-
es including upregulation of UCP2 induced by these nuclear receptors
are required only during prolonged phagocytosis, when macrophages
not only take up apoptotic cells, but also have to handle the digested
material 3.) though the induction of C1q was LXR-dependent, in the
presence of serum which contains complement factors, the lack of C1q
production by macrophages following LXR silencing could not result
in a detectable effect on the Dex-induced short-term efferocytosis.However, glucocorticoid-induced prolonged phagocytosis tested
after exposure of macrophages to apoptotic cells for 3 h was LXR- and
PPARδ-dependent (Fig. 5B) and required the retinoid production in-
duced by LXRs (Fig. 6), in line with the observation that the full upreg-
ulation and activity of these nuclear receptors was dependent on the
endogenously produced retinoids. Besides enhancing the expression
of phagocytic receptors known to be triggered by nuclear receptors fol-
lowing exposure to the lipid content of the apoptotic cells [17–23], nu-
clear receptors promoted prolonged phagocytosis very likely also via
inducing alterations in metabolism [24,25], as well as via increasing
the expression of UCP2 [27] needed to handle the digestedmaterial dur-
ing continued clearance of apoptotic cells. Altogether our data indicate
that glucocorticoids promote not only the short-term, but also the
long-term phagocytosis of apoptotic cells, and they act so by upregulat-
ing the lipid sensing receptors LXRs and PPARδ. Since retinoids mediate
the glucocorticoid effect on long-term efferocytosis, retinoids could be
considered as potential promoters of the efﬁciency of glucocorticoid
treatment in inﬂammatory diseases.5. Conclusions
Glucocorticoids enhance both short-term and continued phagocyto-
sis of apoptotic cells. Short-term phagocytosis is enhanced mainly by
upregulation of MERTK and C1q expression levels, while continued
phagocytosis is promoted via the induction of LXRs, PPARδ and UCP2.
The full upregulation of these molecules by glucocorticoids involves
newly synthetized retinoids, which amplify the expression of these
molecules in an autoregulatory positive loop (Fig. 7).Acknowledgements
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